The sector's revaluation is on, and these names in particular have made some stunning moves.
Amgen, Celgene and Pharmacyclics see short interest drop recently.
This leading company is conducting 25 late-stage clinical trials for new drugs.
Despite trading near its 52-week high, the stock appears to have plenty left.
Higher federal mandates are creating a big opportunity in this alternative energy industry. Here are the best stocks in the sector.
This ETF provides a diversified way to invest across the sector.
This biotech behemoth's appeal is its combined value-and-growth stock characteristics.
VIDEO ON MSN MONEY
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.
MONEY & POLITICS
Breaking up big banks is an untested solution to the too big to fail problem that attempts to isolate and dismantle large, troubled institutions while protecting the rest of the economy.
Joe Cantrell says he faces charges after trying to take advantage of the retailer's policy.
The IRS is struggling to combat identify thieves who file fraudulent tax returns in the names of older residents who don't need to file.